Published

Post-infusion monitoring periods may include the initiation of fluoropyrimidine- and platinum-containing chemotherapy

  • Fluoropyrimidine- and platinum-containing chemotherapy may be included during the zolbetuximab post-infusion monitoring period.1
  • In Phase 3 clinical trials SPOTLIGHT and GLOW, mFOLFOX6 and CAPOX could be given during the zolbetuximab post-infusion observation period.2,3

  • Monitor patients for hypersensitivity reactions at least two hours after the first infusion. For subsequent infusions, monitor approximately two hours if Grade ≥ 2 adverse events were observed during the first infusion or post-infusion monitoring period, or at least one hour in their absence.1
  • More information on adjustments to the observation period can be accessed using the link below:

  1. Data on File.

  2. Shitara K, Lordick F, Bang YJ, et al. Supplement to: Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023;401(10389):1655-1668. Available at: https://doi.org/10.1016/s0140-6736(23)00620-7.

  3. Shah MA, Shitara K, Ajani JA, et al. Supplement to: Zolbetuximab plus CAPOX in CLDN18.2- positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat. Med. 2023;29(8):2133-2141. Available at: https://doi.org/10.1038/s41591-023-02465-7.

If you are not able to find the information through the Search function, please contact our Medical Communications and Engagement Department by using any of the channels below:

Connect with Field Medical

Connect with Field Medical

Medical Science Liaisons (MSLs) and Medical Value and Access (MV&A) team members are available to help answer your scientific and health economic questions.

 

Submit an Inquiry

Submit an Inquiry

For any medical inquiries, please submit your question online to Astellas Medical Information or call or fax your inquiry.

Astellas Phone: 1-800-727-7003

Fax: 1-877-829-7942

Hours: M–F, 8 AM–4:30 PM (CT)

Report an Adverse Event or Product Complaint

Report an Adverse Event or Product Complaint

Report adverse events and product complaints to Astellas or FDA MedWatch.

Astellas Phone: 1-800-727-7003

FDA MedWatch: 1-800-FDA-1088

Hours: M–F, 8 AM–4:30 PM (CT)